Physician profile
Esther Lee Kim
NPI 1649539404
$366,679.94
in general payments reported to CMS, 2019-2025
25 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $138 · 2021: $549 · 2022: $11K · 2023: $65K · 2024: $146K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $149K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Travel and Lodging: $25K · Honoraria: $20K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $149,440.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $134,098.83 |
| Travel and Lodging | $24,921.79 |
| Honoraria | $19,760.50 |
| Food and Beverage | $13,777.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,694.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $111,229.22 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $89,781.49 | 2022-2025 | Syfovre, Syfovre |
| Astellas Pharma US INC | $86,799.71 | 2023-2025 | Izervay |
| Genentech USA, INC. | $41,532.63 | 2019-2025 | Vabysmo, Susvimo |
| Ani Pharmaceuticals, INC. | $10,738.21 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Regeneron Pharmaceuticals, INC. | $8,134.42 | 2022-2024 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $4,009.76 | 2019-2024 | Iluvien, Yutiq |
| Ocular Therapeutix, INC. | $3,498.72 | 2024-2025 | Dextenza |
| Alcon Vision LLC | $3,156.39 | 2023-2025 | Clareon, Centurion, Tryptyr |
| Neurotech Pharmaceuticals, INC. | $2,971.55 | 2025 | |
| Genentech, INC. | $1,645.90 | 2024-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $747.74 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $515.90 | 2021-2025 | Acthar |
| Notal Vision, INC. | $356.98 | 2022 | |
| Harrow Eye, LLC | $336.94 | 2024-2025 | Iheezo, Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $289.99 | 2022-2025 | Xipere, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $254.94 | 2019-2023 | |
| Astellas Pharma Global Development | $199.77 | 2024-2025 | Izervay |
| Biogen, INC. | $114.73 | 2022-2023 | |
| Glaukos Corporation | $112.91 | 2022 | |
| Oyster Point Pharma, INC. | $86.74 | 2023-2025 | Tyrvaya, Ryzumvi |
| Eyepoint US, INC. | $73.09 | 2019-2022 | |
| Coherus Oncology, INC. | $39.69 | 2023 | |
| Horizon Therapeutics Plc | $33.29 | 2023 | Tepezza |
| Amgen INC. | $19.23 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.